Abstract
Recombinant immunotoxins are extremely promising agents for the targeted therapy of tumors with a certain molecular profile. In this work, we studied the properties of a new recombinant HER2-specific immunotoxin composed of the scFv antibody and a fragment of Pseudomonas exotoxin A (4D5scFv-PE40). High affinity of the immunotoxin for the HER2 tumor marker, its selective cytotoxicity against HER2-overexpressing cells, and its storage stability were demonstrated. The 50% inhibitory concentration (IC50) of the 4D5scFv-PE40 immunotoxin for HER2-overexpressing cancer cells was 2.5-3 orders of magnitude lower compared to that for CHO cells not expressing this tumor marker and was 2.5-3 orders of magnitude lower than IC50 of free PE40 for HER2-overexpressing cancer cells. These findings provide a basis for expecting in the long run high therapeutic index values of the 4D5scFv-PE40 immunotoxin for its use in vivo.
Original language | English |
---|---|
Pages (from-to) | 93-96 |
Number of pages | 4 |
Journal | Acta Naturae |
Volume | 7 |
Issue number | 4 |
Publication status | Published - 2015 |
Externally published | Yes |
Keywords
- 4D5scFv
- HER2 tumor marker
- Pseudomonas exotoxin A
- Recombinant immunotoxin
- Targeted therapy
ASJC Scopus subject areas
- Biochemistry
- Biotechnology
- Molecular Biology
- Molecular Medicine